Evaluation of the Prothrombin Time for Measuring Rivaroxaban Plasma Concentrations Using Calibrators and Controls

New oral antithrombotics: a need for laboratory monitoring. For

(2010) P. MISMETTI et al.   JOURNAL OF THROMBOSIS AND HAEMOSTASIS

New oral antithrombotics: a need for laboratory monitoring. Against

(2010) H. BOUNAMEAUX et al.   JOURNAL OF THROMBOSIS AND HAEMOSTASIS

The International Normalized Ratio calibrated for rivaroxaban has the potential to normalize prothrombin time results for rivaroxaban-treated patients: results of an in vitro study

(2010) A. TRIPODI et al.   JOURNAL OF THROMBOSIS AND HAEMOSTASIS

Assessment of laboratory assays to measure rivaroxaban – an oral, direct factor Xa inhibitor

(2010) Jean-Luc Martinoli et al.   THROMBOSIS AND HAEMOSTASIS

Population Pharmacokinetics and Pharmacodynamics of Rivaroxaban – an Oral, Direct Factor Xa Inhibitor – in Patients Undergoing Major Orthopaedic Surgery

(2009) Wolfgang Mueck et al.   CLINICAL PHARMACOKINETICS

Dose-escalation study of the pharmacokinetics and pharmacodynamics of rivaroxaban in healthy elderly subjects

(2008) Dagmar Kubitza et al.   CURRENT MEDICAL RESEARCH AND OPINION

Determination of rivaroxaban – a novel, oral, direct Factor Xa inhibitor – in human plasma by high-performance liquid chromatography–tandem mass spectrometry

(2008) G. Rohde   JOURNAL OF CHROMATOGRAPHY B-ANALYTICAL TECHNOLOGIES IN THE BIOMEDICAL AND LIFE SCIENCES